Many companies featured on Money advertise with us. Opinions are our own, but compensation and
in-depth research may determine where and how companies appear. Learn more about how we make money.

  1. Shopping
  2. Health Products

A Totally Free EpiPen Alternative Will Soon Hit the Market

By: Brad Tuttle
Brad Tuttle, expert in Personal finance, shopping, consumer trends, and Senior Editor at Money
Brad Tuttle
Senior Editor | Joined January 2014
Brad Tuttle is a senior editor at Money with over 10 years’ experience covering a vast number of personal finance topics, including careers, cars, travel, budgeting, investing, insurance, credit cards, consumer psychology, real estate, banking, and shopping and deals.
See full bio
Published: Jan 19, 2017 3 min read
Protestors Rally In New York Against EipPen Price Gouging Scandal
In the wake of last summer's protests over EpiPen price gouging, low-priced competitors have emerged in early 2017.
Drew Angerer—Getty Images

One week after CVS announced it is introducing an EpiPen alternative for $10, another competitor to the notoriously expensive allergy prescription is back—and will be totally free for most people.

Auvi-Q, an auto-adrenaline-injection system that's similar to EpiPen and was recalled last fall, safely returns to the market by February 14, according to manufacturer Kaleo Pharma. The regular price will be $360, but there will be two different ways to get Auvi-Q for free.

Anyone with health insurance—including those with high-deductible plans—will be provided with Auvi-Qs at no cost out of pocket. The product will also be free of charge to patients without insurance who live in households with annual income under $100,000. Considering that the vast majority of Americans have insurance, and those who don't are highly likely to be poor, it seems like these provisions would cover nearly everyone.

Spencer Williamson, president and CEO of Kaleo, told reporters on Thursday, "No epinephrine auto-injector, branded or even generic, will cost a commercially insured patient less out of pocket than Auvi-Q."

The new product release comes after months of bad publicity for Mylan, the maker of EpiPen, which came under fire last summer for gouging customers with $600+ retail prices for its lifesaving product, an auto-injection adrenaline system that wards off anaphylactic shock during a severe allergy attack. After being bashed by parents, politicians, and consumer watchdogs for jacking prices up 500% over a decade, Mylan has offered more generous coupons and introduced a generic EpiPen in recent months.

But Mylan may lose its near-monopoly on the allergy prescription market anyway, as a variety of alternatives hit the scene and undercut the company on pricing. CVS Health recently said that it will sell a generic version of an EpiPen alternative known as Adrenaclick at a list price of $110 for a two-pack. Once this coupon is factored in, $100 will be deducted from the price and most customers will pay only $10.

But once Kaleo's free EpiPen alternative is available, even paying $10 may seem like too much.